Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Volpe Discusses the Management of Localized Kidney Cancer

November 18th 2017

Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.

Pembrolizumab, Atezolizumab New Standards for Bladder Cancer

November 18th 2017

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

Combining Partial Metastasectomy With Systemic Treatment Beneficial in mRCC

November 18th 2017

The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

November 17th 2017

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.

Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCC

November 17th 2017

Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).

FDA Approves Adjuvant Sunitinib for High-Risk RCC

November 17th 2017

The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are high risk for recurrence.

Cabozantinib RCC Benefit Highlighted as Frontline Approval Approaches

November 16th 2017

Cabozantinib (Cabometyx) remains to be the sole oral drug to meet 3 clinical trial endpoints of progression-free survival, overall survival, and overall response rate in patients with advanced RCC.

Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

November 15th 2017

Matthew Galsky, MD, professor of medicine, hematology and medical oncology, Mount Sinai Hospital, discusses resistance to checkpoint blockade in metastatic bladder cancer.

Prostate Cancer Paradigm Expanding With Ongoing Research

November 15th 2017

Przemyslaw W. Twardowski, MD, discusses a variety of factors to consider when treating patients with prostate cancer.

Dr. Agarwal on Remaining Questions With Renal Cell Carcinoma

November 14th 2017

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses remaining questions in renal cell carcinoma.

Expert Discusses Degarelix and Other Developments in Prostate Cancer

November 14th 2017

Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.

Pal Shares Insight on Abundance of Options in GU Malignancies

November 14th 2017

Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.

Dr. Grivas on Combining Chemotherapy and Immunotherapy in Bladder Cancer

November 14th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses combining chemotherapy and immunotherapy as a treatment approach for patients with bladder cancer.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers

November 12th 2017

The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.

Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced Cancers

November 12th 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.

Dr. Uzzo on Biomarker Development for RCC

November 10th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

Dr. Hope on the Future of Imaging for Biochemical Recurrent Prostate Cancer

November 10th 2017

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco (UCSF), discusses the future of imaging for biochemical recurrent prostate cancer.

Dr. Inman on Biomarkers for Immunotherapy in Bladder Cancer

November 10th 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center discusses biomarkers for immunotherapy in patients with bladder cancer.

Checkpoint Inhibitors Herald a New Era for Treating Urothelial Cancer

November 7th 2017

Decades of clinical trials exploring modifications of cytotoxic regimens, including the use of different or more drugs, demonstrated that a therapeutic plateau had been reached with conventional chemotherapeutic agents, highlighting the need for novel approaches in urothelial carcinoma.